23:11 , Feb 24, 2017 |  BioCentury  |  Product Development

Dendritic cell control

Denceptor Therapeutics Ltd. is developing a technology for inducing antigen-specific T cell responses that the company believes will be more efficacious than other dendritic cell-targeted approaches for cancer while avoiding the safety issues raised by...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Varlilumab: Phase I/II started

Celldex began an open-label, U.S. Phase I/II trial to evaluate IV varlilumab and its subcutaneous CDX-1401 in combination with Yervoy ipilimumab and the adjuvant poly-ICLC in about 100 patients. The Phase I portion will test...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

CDX-1401: Phase I/II started

Celldex began an open-label, U.S. Phase I/II trial to evaluate its IV varlilumab ( CDX-1127 ) and subcutaneous CDX-1401 in combination with Yervoy ipilimumab and the adjuvant poly-ICLC in about 100 patients. The Phase I...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

CDX-1401: Additional Phase I data

Celldex expects the Cancer Immunotherapy Trials Network (CITN) to begin a trial of CDX-1401 next year, but the company said that the indication and trial design are yet to be determined. The National Cancer Institute...
08:00 , Jan 12, 2012 |  BC Innovations  |  Tools & Techniques

Trypping up tumors

A major limitation of many cancer immunotherapies is their inability to trigger a potent CD8 + T cell response, which is critical for battling different types of tumors. Brazilian and U.S. researchers may have solved...
07:00 , Apr 28, 2011 |  BC Innovations  |  Tools & Techniques

Next-generation dendritic cell vaccines

Vaccine makers have known for years that delivering immunogenic antigens to dendritic cells can elicit the strong T cell-based immune response that is key to combating viral and bacterial infections and cancer. But complexities of...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Clinical News

CDX-1401: Preliminary Phase I/II data

Preliminary data from an ongoing, open-label, dose-escalation, U.S. Phase I/II trial in 20 patients, 35% of which had confirmed NY-ESO-1 expression, showed that subcutaneous CDX-1401 plus resiquimod as an adjuvant produced 6 cases of stable...
07:00 , May 3, 2010 |  BioCentury  |  Product Development

Building on Provenge

Last week's FDA approval of Provenge to treat metastatic prostate cancer has established immunotherapy as part of the cancer armamentarium. The question is what now will be done to build on what has been learned...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Clinical News

CDX-1401: Phase I/II started

Celldex began an open-label, dose-escalation, U.S. Phase I/II trial in about 36 patients to evaluate 3 dosages of subcutaneous CDX-1401 given every 2 weeks for 4 doses in combination with resiquimod, a toll-like receptor 7...
07:00 , Jun 1, 2009 |  BioCentury  |  Finance

Ebb & Flow

On its face, the deal to take out CuraGen Corp. (NASDAQ:CRGN) is returning about $0.18 for every dollar the genomics-based oncology company has raised since it went public. But the $94.5 million all-stock offer announced...